Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
36.99
+2.09 (+5.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
February 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
January 29, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)
↗
January 24, 2025
Via
Benzinga
Where NewAmsterdam Pharma Stands With Analysts
↗
December 30, 2024
Via
Benzinga
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
January 16, 2025
Via
Benzinga
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
January 10, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
↗
December 05, 2024
Via
Benzinga
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
↗
November 11, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma
↗
November 07, 2024
Via
Benzinga
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
↗
December 15, 2024
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.
Via
Benzinga
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 13, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 11, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
↗
December 11, 2024
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.
Via
Investor's Business Daily
Top 3 Health Care Stocks That May Collapse This Quarter
↗
December 11, 2024
Via
Benzinga
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 10, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 10, 2024
Via
Benzinga
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
↗
December 10, 2024
NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH patients on standard therapy.
Via
Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
↗
December 10, 2024
Via
Benzinga
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
↗
December 10, 2024
The results bode well for an ongoing Phase 3 study examining cardiovascular outcomes.
Via
Investor's Business Daily
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
December 10, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
↗
November 20, 2024
The company's combination treatment lowered LDL cholesterol by about 50% over 84 days.
Via
Investor's Business Daily
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
November 20, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
November 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 06, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
October 28, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
